Pennington Biomedical Research Center
pbrc.eduTotal trials
281
Active
47
Phase 3
1
Total enrollment
65,421
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Tirzepatide | — | — | — | — | 2 | ||
| Pioglitazone 45 mg | — | — | — | — | — | 1 | |
| Fecal microbial diversity | — | — | — | — | — | 1 |
Next readouts
- 2025-06-30
- 2026-12-31
- 2027-02-01
Top conditions
- Obesity49
- Childhood Obesity14
- Insulin Resistance12
- Type 2 Diabetes8
- Weight Loss8
- Insulin Sensitivity8
- Overweight7
- Diabetes Mellitus, Type 26
Frequently asked questions about Pennington Biomedical Research Center
- How many clinical trials does Pennington Biomedical Research Center have on ClinicalTrials.gov?
- Pennington Biomedical Research Center is listed as the lead sponsor on 281 clinical trials in ClinicalTrials.gov, 47 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Pennington Biomedical Research Center's trials are in Phase 3?
- 1 of Pennington Biomedical Research Center's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Pennington Biomedical Research Center focus on?
- Pennington Biomedical Research Center's most-studied conditions on ClinicalTrials.gov are Obesity, Childhood Obesity, Insulin Resistance, Type 2 Diabetes, Weight Loss.
- When are Pennington Biomedical Research Center's next clinical trial readouts?
- Pennington Biomedical Research Center has 3 upcoming primary-completion readouts tracked here; the soonest is “The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia”, expected around 2025-06-30.